Kamada (KMDA)
NASDAQ:KMDA
Earnings Data
Report Date
Aug 19, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.11Last Year’s EPS
0.13Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced clear operational progress and strategic catalysts—reaffirmed 2026 guidance, FDA approval of a plasma center, expanding commercial and distribution initiatives, growing utilization of key products, and a maintained dividend—with near‑term headwinds including a shipment delay, gross margin compression, and slight cash reduction following the dividend. Management emphasized organic growth drivers and M&A/business development opportunities, and adjusted EBITDA and net income trends were stable to modestly improved, supporting a constructive outlook despite some quarter‑specific challenges.Company Guidance
Reaffirmed 2026 Guidance
Company reiterated full-year 2026 guidance of $200M–$205M in revenues and $50M–$53M in adjusted EBITDA, which management states represents ~12% revenue growth and ~23% adjusted EBITDA growth at the guidance midpoint versus 2025, based solely on organic growth.
Q1 Profitability and Adjusted EBITDA
Net income of $4.1M ($0.07 per diluted share), up ~4% versus prior year comparable quarter; adjusted EBITDA of $11.6M in Q1 2026, reported as essentially flat year-over-year.
Product Commercial Momentum — KEDRAB and GLASSIA
KEDRAB (anti‑rabies) end‑user utilization in the U.S. is increasing significantly; supply to Kedrion expected to exceed Kedrion's $90M minimum commitment for 2026–2027 with supply agreement through 2031. GLASSIA growth driven by ex‑U.S. sales and royalty income from Takeda in U.S./Canada.
CYTOGAM Post‑Marketing Program Showing Positive Signals
Expanded post‑marketing clinical program for CYTOGAM including the SHIELD study and investigator reports (e.g., ISHLT presentation) that management believes will support increased utilization in high‑risk transplant patients.
Plasma Collection Progress and FDA Approval
FDA approval received for San Antonio plasma center; company plans to begin commercial normal source plasma sales in H2 2026. Houston and San Antonio centers each are expected to generate $8M–$10M in annual revenue at full capacity; full collection capacity expected end of 2027–early 2028.
Distribution & Biosimilars Expansion
Distribution portfolio in Israel comprises ~40 products today and expected to be ~45 by year‑end; two additional biosimilars launching soon with management targeting biosimilars annual sales of $15M–$20M within 4–5 years and expansion into the MENA region underway.
Cash Return to Shareholders
Declared and paid a cash dividend of $0.25 per share (~$14.4M) in April, reflecting board confidence in liquidity and future prospects and an annual dividend policy of at least 50% of annual net income (subject to board discretion).
Cost Discipline on Operating Expenses
Operating expenses decreased to $12.1M in Q1 2026 from $13.0M in Q1 2025, driven primarily by reduced R&D spend following termination of the Phase III InnovAATe trial, partially offset by higher sales & marketing and G&A investments to support growth.
KMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KMDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $8.43 | $7.86 | -6.76% |
Mar 11, 2026 | $8.70 | $8.30 | -4.58% |
Nov 10, 2025 | $6.46 | $6.81 | +5.40% |
Aug 13, 2025 | $7.26 | $7.16 | -1.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kamada (KMDA) report earnings?
Kamada (KMDA) is schdueled to report earning on Aug 19, 2026, Before Open (Confirmed).
What is Kamada (KMDA) earnings time?
Kamada (KMDA) earnings time is at Aug 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KMDA EPS forecast?
KMDA EPS forecast for the fiscal quarter 2026 (Q2) is 0.11.